Zacks Investment Management Erasca, Inc. Transaction History
Zacks Investment Management
- $10.5 Billion
- Q1 2025
A detailed history of Zacks Investment Management transactions in Erasca, Inc. stock. As of the latest transaction made, Zacks Investment Management holds 23,057 shares of ERAS stock, worth $35,738. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,057Holding current value
$35,738% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ERAS
# of Institutions
164Shares Held
222MCall Options Held
20.6KPut Options Held
5.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.6MShares$35 Million1.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.3MShares$26.8 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$25.1 Million5.36% of portfolio
-
Logos Global Management LP San Francisco, CA13MShares$20.2 Million3.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$19.7 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $189M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...